Perspective Therapeutics, Inc. 8-K

What Happened
Perspective Therapeutics, Inc. (CATX) filed an 8-K on February 2, 2026 to disclose an updated corporate presentation posted to its website. The Presentation includes preliminary, estimated and projected financial information — notably the company’s estimated cash, cash equivalents and short‑term investments as of December 31, 2025. The company notes these figures are preliminary and unaudited; WithumSmith+Brown, PC (the independent registered public accounting firm) has not performed any procedures or provided assurance on the data. The filing was signed by Joel Sendek, Chief Financial Officer.

Key Details

• Filing date: February 2, 2026 (8-K Items 2.02 and 8.01).
• Presentation posted to the company website and filed as Exhibit 99.1.
• Contains preliminary estimated cash, cash equivalents and short‑term investments as of December 31, 2025 (no audited amounts provided).
• Independent auditor Withum did not review or provide assurance on the preliminary financial information; actual results may change after closing procedures and final adjustments.

Why It Matters
This notifies investors that the company has disclosed a preliminary snapshot of its year‑end liquidity but that the figures are unaudited and subject to change. For retail investors, the key takeaway is that the company is providing updated liquidity information ahead of audited year‑end financial statements; investors should wait for the finalized, audited results before drawing firm conclusions about cash position, runway or implications for earnings and operations.